Therefore, blocking the positive regulatory loop consisting of gankyrin/STAT3/CCL24/CCR3 through gankyrin knockdown or treatment with the CCR3 inhibitor reverses the pazopanib resistance of ccRCC in vivo. The gene discussed is CCR3; the disease is nonpapillary renal cell carcinoma.